Divaya Bhutani1, Lawrence G Lum. 1. aDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA bDepartment of Immunology and Microbiology, Wayne State University and Barbara Ann Karmanos Cancer Center, Detroit, Michigan, USA.
Abstract
PURPOSE OF REVIEW: Adoptive T-cell therapy has become one of the most exciting fields of cancer therapy in the past few years. In this article, we describe a method which combines adoptive T-cell therapy with antibody therapy by arming T cells from cord blood, normal patients, and cancer patients with bispecific antibodies capable of binding to tumor-associated antigens on one side of the bispecific antibody construct and T cells on another side of the construct. This approach redirects T cells against tumor cells in a non-MHC-restricted manner. RECENT FINDINGS: Various methods for manipulating the immune system including check-point inhibitors, chimeric antigen receptor T cells, and bispecific antibodies have shown promising activity in treating both hematological malignancies and solid tumors with excellent success. In recent studies, activated T cells armed with bispecific antibodies have shown good preclinical activity, safety, and promising efficacy in the clinical trials. SUMMARY: Activated T cells armed with bispecific antibodies represent a promising treatment for cancer immunotherapy.
PURPOSE OF REVIEW: Adoptive T-cell therapy has become one of the most exciting fields of cancer therapy in the past few years. In this article, we describe a method which combines adoptive T-cell therapy with antibody therapy by arming T cells from cord blood, normal patients, and cancerpatients with bispecific antibodies capable of binding to tumor-associated antigens on one side of the bispecific antibody construct and T cells on another side of the construct. This approach redirects T cells against tumor cells in a non-MHC-restricted manner. RECENT FINDINGS: Various methods for manipulating the immune system including check-point inhibitors, chimeric antigen receptor T cells, and bispecific antibodies have shown promising activity in treating both hematological malignancies and solid tumors with excellent success. In recent studies, activated T cells armed with bispecific antibodies have shown good preclinical activity, safety, and promising efficacy in the clinical trials. SUMMARY: Activated T cells armed with bispecific antibodies represent a promising treatment for cancer immunotherapy.
Authors: Guilin Qiao; Lyonell B Kone; Evan H Phillips; Steve Seung-Young Lee; Grace E Brown; Salman R Khetani; Archana Thakur; Lawrence G Lum; Bellur S Prabhakar; Ajay V Maker Journal: Oncogene Date: 2022-02-17 Impact factor: 8.756